Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation
Published in
European Journal of Pharmaceutics & Biopharmaceutics, October 2022
Pharmacology, Toxicology and Pharmaceutical Science
3
18%
Biochemistry, Genetics and Molecular Biology
1
6%
Nursing and Health Professions
1
6%
Sports and Recreations
1
6%
Medicine and Dentistry
1
6%
Other
0
0%
Unknown
10
59%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#23,108,329
of 34,547,233 outputs
Outputs from European Journal of Pharmaceutics & Biopharmaceutics
#2,455
of 3,482 outputs
Outputs of similar age
#244,194
of 464,389 outputs
Outputs of similar age from European Journal of Pharmaceutics & Biopharmaceutics
#19
of 75 outputs
Altmetric has tracked 34,547,233 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,482 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 464,389 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
